From weeks to hours - the rapid new test transforming brain tumour diagnosis

A rapid genomic test that can identify the exact type of brain tumour within two hours is now being used by the NHS, cutting the traditional diagnostic window of up to eight weeks dramatically. The test, which analyses the DNA of a tumour sample on a portable Oxford Nanopore sequencer, was employed during the operation of 55‑year‑old Steve Palmer at Queens Medical Centre in Nottingham, allowing surgeons to receive a provisional diagnosis of grade‑4 glioblastoma while the patient was still on the operating table. Palmer, who collapsed at a gym and was subsequently diagnosed, said the swift result eliminated weeks of anxiety and enabled him to move quickly into the next phase of treatment. Consultant neurosurgeon Stuart Smith described the technology as “almost magical,” noting that the rapid molecular classification can inform whether surgeons should pursue an aggressive resection or adopt a more cautious approach to preserve brain function.

The test’s impact extends beyond individual cases, offering a transformative solution to a diagnostic bottleneck that has long delayed treatment for the roughly 12,000 UK patients diagnosed with primary brain tumours each year. Traditional pathology relies on microscopic examination and can take six to eight weeks to deliver a full molecular profile, a delay that is especially critical for aggressive tumours where timely therapy can affect survival. By sequencing DNA through a nanopore—where molecules pass through a tiny hole and generate a unique genomic fingerprint—the system provides a comprehensive molecular classification that surpasses the limited insight of conventional microscopy. Dr. Simon Paine, a consultant neuropathologist, emphasized that the nanopore’s clarity is far superior to “crystal ball gazing” with a microscope, delivering actionable data that can guide both surgical strategy and subsequent oncological treatment.

The NHS England pilot, described as a “world first,” will initially involve five specialist centres—Nottingham, Birmingham, London, Newcastle and Great Ormond Street—and later expand to Bristol, Oxford, Leeds and Manchester. The programme builds on earlier projects in Nottingham and Birmingham and is supported by senior NHS officials, including Prof. Frankie Swords and Prof. Dame Sue Hill, who highlighted the test’s potential to shorten diagnostic waits, enable earlier access to appropriate therapies or clinical trials, and allow surgeons to make life‑changing intra‑operative decisions. As the pilot gathers evidence, the technology could become a standard component of brain‑tumour care across the NHS, reshaping the diagnostic pathway for patients and their families and setting a precedent for rapid genomic testing in other cancer types.

⚡ Effects Interpreter